AtriCure projects 2026 adjusted EBITDA of $91M-$94M
FROM THE WIRE · SEEKINGALPHA.COM
AtriCure Q3 2026 earnings: revenue rose 15%, EBITDA outlook increased, and BoxX-NoAF nears enrollment amid market headwinds.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA raised EBITDA outlook can support the shares of a small medtech company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01AtriCure projects 2026 adjusted EBITDA of $91M to $94M.
- 02Third-quarter revenue rose 15%.
- 03The company targets completing BoxX-NoAF enrollment by year-end.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets